Two RSV Platforms for G, F, or G+F Proteins VLPs

Respiratory syncytial virus (RSV) causes substantial lower respiratory tract disease in children and at-risk adults. Though there are no effective anti-viral drugs for acute disease or licensed vaccines for RSV, palivizumab prophylaxis is available for some high risk infants. To support anti-viral a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ha, Binh, Yang, Jie E., Chen, Xuemin, Jadhao, Samadhan J., Wright, Elizabeth R., Anderson, Larry J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551478/
https://www.ncbi.nlm.nih.gov/pubmed/32824936
http://dx.doi.org/10.3390/v12090906

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551478/
https://www.ncbi.nlm.nih.gov/pubmed/32824936
http://dx.doi.org/10.3390/v12090906

Ejemplares similares